AstraZeneca Shares Top FTSE 100 Index Risers After Tagrisso Gets U.S. Approval
By Ian Walker
AstraZeneca shares are up and leading the FTSE 100 index risers after the company said that its lung-cancer treatment Tagrisso, together with chemotherapy, has been approved in the U.S.
Shares at 1103 GMT were up 304.0 pence, or 3%, at 10,398 pence. However, they are down 9.4% over the past 12 months.
The pharmaceutical giant said Monday that the approval was based on trial results which showed that Tagrisso plus chemotherapy extended median progression-free survival by nearly nine months when compared with standard of care.
The approval is for adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
The trial involved 557 patients in over 150 centers across more than 20 countries, including in the U.S., Europe, South America and Asia.
"This important new treatment option can delay disease progression by nearly nine additional months, establishing a new benchmark with the longest reported progression-free survival benefit in the 1st-line advanced setting," Dave Fredrickson, executive vice president, oncology business unit, said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
February 19, 2024 06:40 ET (11:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths